The demo obtained both equally its Most important endpoints, with semaglutide 2.4 mg demonstrating statistically considerable and exceptional enhancements in liver fibrosis with no worsening of steatohepatitis, and also resolution of steatohepatitis without having worsening of liver fibrosis in people with MASH in comparison to placebo.oneExcretion